Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Inclusion Criteria:

• Stable health status
• Access to a consistent means of telephone contact.
• Comprehension of study requirements, availability for study duration
• Availability and ability to attend scheduled visits
• Females post menopausal, sterile or using accepted contraceptive measures
• Competence to provide informed consent

Exclusion Criteria:

• Presence of significant acute or chronic medical or neuropsych. illness
• New medical or surgical treatment w/i 1 month
• Change in medication dose due to uncontrolled symptoms w/i 1 month
• Hospitalization w/i 1 month
• Any unusual risk (for age group) of serious adverse events w/i 1 month
• Any neuropsychiatric condition altering competence for consent
• Any neuropsychiatric condition preventing accurate safety reports
• Febrile illness on day of treatment
• Employment in professions at high risk of influenza transmission
• Residence in a long-term-care facility or with an immunocompromised person
• Systolic BP over 150, diastolic over 90, resting pulse under 50 or over 100
• Cancer w/i 3 years
• Immunosuppressive of immunodeficient conditions
• Treatment with systemic glucocorticoids > replacement
• Treatment with cytotoxic or immunosuppressant drugs
• Treatment with immune globulins
• Clotting disorders that increase the risks of intramuscular injections
• History of demyelinating disease or GBS
• Pregnancy or nursing
• Absence of contraceptive practices in women with childbearing potential
• Planned administration of non-influenza vaccines within 30 days
• Receipt of any investigational drug within 30 days
• Receipt of immune globulin treatment within 3 months
• Known or suspected allergy to egg proteins, gelatin, or thimerosal
• History of severe adverse reactions toflu vaccines
• Prior receipt of 2005-6 influenza vaccine